论文部分内容阅读
目的探讨干扰素对慢性乙肝患者CD25的诱导及其对PBMC内的HBV-DNA的抗病毒作用。方法将94例慢性乙肝患者分为A(48例)、B(46例)两组,分别采用IFN-α2b和常规治疗2个疗程。应用生物素-链霉亲和素(biotin-streptavidin,BSA)法检测治疗前后的及PHA体外诱导后的患者PBMC的CD25表达水平;每疗程前后用RT-PCR法检测患者PBMC的CD25 mRNA表达水平;FQ-PCR法动态检测患者HBV-DNA载量。结果慢性乙肝患者的PBMC静息态和诱导态的CD25表达水平均降低,干扰素治疗后,静息态和诱导态CD25表达水平逐渐升高,第1疗程后与常规治疗组相比差异具有统计学意义(P<0.05);第2疗程后,2组间差异亦具有统计学意义(P<0.01)。随疗程延长干扰素组与常规组患者CD25 mRNA的表达都逐渐增高,但干扰素组高于常规组,且第2疗程后,2组比较差异具有统计学意义(P<0.05)。疗程结束后,应用干扰素治疗者血清与PBMC内HBV-DNA抗病毒有效率均高于常规治疗组,2组比较差异具有统计学意义(P<0.05)。结论 IFN-α2b可诱导慢性乙肝患者表达CD25增高,促进T细胞活化发挥抗HBV-DNA作用,且疗效优于常规治疗者。
Objective To investigate the induction of CD25 by interferon in patients with chronic hepatitis B and its anti-virus effect on HBV-DNA in PBMC. Methods Ninety-four patients with chronic hepatitis B were divided into two groups: A (48 cases) and B (46 cases). Two courses of IFN-α2b and routine treatment were used. The levels of CD25 in peripheral blood mononuclear cells of PBMCs before and after PHA treatment were detected by biotin-streptavidin (BSA) assay. The levels of CD25 mRNA in PBMCs were detected by RT-PCR before and after treatment FQ-PCR method was used to detect HBV-DNA load dynamically. Results The levels of resting and induced CD25 in PBMC of chronic hepatitis B patients were decreased. After interferon treatment, the levels of resting and induced CD25 were gradually increased, and the difference was statistically significant after the first course of treatment as compared with the conventional treatment group (P <0.05). After the second course of treatment, the differences between the two groups were also statistically significant (P <0.01). The expression of CD25 mRNA in patients with IFN-γ and IFN-α increased gradually with the course of treatment, but the expression of CD25 mRNA in interferon group was higher than that in the conventional group. After the second course, the difference was statistically significant (P <0.05). After treatment, the effective rate of HBV-DNA antivirus in serum and PBMC of patients receiving interferon treatment was higher than that of conventional treatment group. The difference between the two groups was statistically significant (P <0.05). Conclusions IFN-α2b can induce the expression of CD25 in chronic hepatitis B patients and promote the activation of T cells to exert anti-HBV-DNA effect, which is superior to conventional therapy.